Integrating Bioenergetic Therapy Model with Neuropsychopharmacological Interventions in Long-standing Treatment-resistant Schizophrenia: Case Series and Review of Literature
Abstract
Background: The bioenergetic therapy model combines holistic somatic therapy with psychotherapy, addressing both physical and emotional aspects of healing. In cases of long-standing treatment-resistant schizophrenia (TRS), which may persist for over two decades, finding effective therapeutic strategies remain a significant challenge. Despite numerous treatment options, no existing reports integrate somatosensory therapy with neuropsychopharmacological interventions for these complex cases.
Purpose: To demonstrate the integration of bioenergetic therapy with neuropsychopharmacological interventions in managing long-standing treatment-resistant schizophrenic cases.
Methods: Two cases of long-standing schizophrenia were illustrated for how we integrated somatosensory bioenergetics principles with neuropsychopharmacology. They had emotional and/or physical abuse in addition to psychotic symptoms without any pre-morbid schizoid/paranoid traits or psychiatric history of substance abuse, and presented to us with complaints of high sensitivity to rejection, persecutory delusions, third-person auditory hallucinations, irritability, episodic aggression, psychomotor retardation, disturbed sleep, and declining professional performance.
Results: A systematic cognitive deficit evaluation, slow building of clozapine (100 mg/day), integration of somatosensory therapy, family system therapy model and cognitive enhancement therapy were integrated. This integration of somatosensory therapy…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.